Close

Veru, Inc. (VERU) Says FDA Granted Fee Waiver for Tamsulosin DRS New Drug Application

March 22, 2018 8:33 AM EDT Send to a Friend
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on urology and oncology, announced that the U.S. Food and Drug Administration ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login